Home
Development Programs
For Investors
News
About Us
- Our Name & Brandmark
- Team
Contact

Menu

Home
Development Programs
For Investors
News
About Us
- Our Name & Brandmark
- Team
Contact

Case Studies

Search for:

Or browse by category

News

All EMD General

Program: EMD-RX5

Program: EMD-RX5

Developing a new cannabinoid formulation for stress, anxiety and …

Program: EMD-003

Program: EMD-003

Developing a new cannabinoid formulation for stress, anxiety and …

DEVELOPMENT PROGRAMS

Ultra-Pure CBD Medicines
MDMA-inspired Medicines
Research & Data Programs

Ultra-Pure CBD Medicines
MDMA-inspired Medicines
Research & Data Programs

FOR INVESTORS

Stock Information
ASX Announcements
Presentations & Videos
Reports & Updates
Corporate Governance

Stock Information
ASX Announcements
Presentations & Videos
Reports & Updates
Corporate Governance

RECENT TWEETS

Over 50 patients are currently enrolled in our pivotal Phase 3 Clinical Trial of EMD-RX5, with 83 patients awaiting dosing & another 1700+ successfully pre-screened. The trial is expected to conclude in July 2023. $EMD Full update 📩 https://t.co/WQPXXzZLWn

© 2023 Emyria Limited

Terms | Privacy | Website by Glide

Phone
08 6559 2800

Email
info@emyria.com

Linkedin Twitter Youtube

First Name*
Last Name*
Email*
Post code
What news are you interested in?*
- Clinical news
- Patient news
- Investor news
- Partners news
CAPTCHA
Comments
This field is for validation purposes and should be left unchanged.

Δ

Search for:

Hit enter to search or ESC to close

Home
Development Programs
For Investors
News
About Us
- Our Name & Brandmark
- Team
Contact

Call 08 6559 2800 Contact